Cyclerion Therapeutics, Inc. (CYCN): Price and Financial Metrics
CYCN Price/Volume Stats
| Current price | $3.04 | 52-week high | $6.75 |
| Prev. close | $2.77 | 52-week low | $1.75 |
| Day low | $2.87 | Volume | 400 |
| Day high | $3.04 | Avg. volume | 3,173 |
| 50-day MA | $3.12 | Dividend yield | N/A |
| 200-day MA | $3.25 | Market Cap | 8.24M |
CYCN Stock Price Chart Interactive Chart >
Cyclerion Therapeutics, Inc. (CYCN) Company Bio
Cyclerion Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovering, development, and commercialization of various treatments for serious and orphan diseases. Its product candidates include Olinciguat, an orally administered vascular soluble guanylate cyclase (sGC) stimulator that is in Phase II studies for the treatment of sickle cell disease (SCD); Praliciguat, an orally administered systemic sGC stimulator that is in Phase II trials for the treatment of diabetic nephropathy and heart failure with preserved ejection fraction; and IW-6463, an orally administered central nervous system (CNS)-penetrant sGC stimulator, which is in Phase I trials for neurodegenerative diseases. The company is also discovering liver-targeted sGC and lung-targeted sGC stimulators. Cyclerion Therapeutics, Inc. was incorporated in 2018 and is headquartered in Cambridge, Massachusetts.
Latest CYCN News From Around the Web
Below are the latest news stories about CYCLERION THERAPEUTICS INC that investors may wish to consider to help them evaluate CYCN as an investment opportunity.
Cyclerion Appoints Regina Graul, Ph.D., as President– Dr. Graul will lead the rebuild of Cyclerion, bringing more than two decades of drug making experience, R&D portfolio leadership, and a deep expertise in company strategy – – Peter Hecht, Ph.D., will continue to work closely with Cyclerion leadership as a strategic consultant and longstanding board member; steps down from CEO role – CAMBRIDGE, Mass., Dec. 04, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a biopharmaceutical company on a mission to develop treatments for |
Cyclerion Strengthens Board of Directors with Experienced Company Builder and Cutting-edge Innovator- Dina Katabi, Ph.D.: World leader in healthcare AI applications at MIT; inventor of groundbreaking wireless devices for passive assessment of symptoms, behavior, and treatment responses in neurological and psychiatric disorders - Michael Higgins: Seasoned biopharma executive possessing business and financial acumen with CEO and extensive board experience; former entrepreneur-in-residence at Polaris Partners with a track record of launching successful companies CAMBRIDGE, Mass., Nov. 30, 2023 (G |
Cyclerion Therapeutics' Market Cap Drops To US$5.0m Leaving Insiders With LossesInsiders who bought US$1.95m worth of Cyclerion Therapeutics, Inc.'s ( NASDAQ:CYCN ) stock at an average buy price of... |
The Petri Dish: Alexion buys Pfizer gene therapies in $1B deal; Peter Hecht's plan to save Cyclerion assetsPeter Hecht, the co-founder and CEO of embattled biotech Cyclerion Therapeutics Inc. (Nasdaq: CYCN), is heading up a new startup that's effectively a life raft for Cyclerion's research. Elsewhere in the Petri Dish: a $1 billion deal for Pfizer gene therapies, a succession plan for a founder-led biotech organization, and a new Longwood Fund spinout with assets from GSK. |
Tisento Launches with $81 Million From Top-Tier Investor Syndicate and Promising Cyclerion Assets– Asset Purchase Agreement Closed; Cyclerion Received Equity Ownership in Tisento and Upfront Cash Payment – – Tisento Developing Zagociguat in MELAS*, a Rare Primary Mitochondrial Disease with No Approved Therapies, Leveraging Extensive Preclinical and Clinical Data Generated by Cyclerion – CAMBRIDGE, Mass., July 31, 2023 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN) and Tisento Therapeutics, Inc. today announced the closing of the previously disclosed asset purchase agreement |
CYCN Price Returns
| 1-mo | -1.31% |
| 3-mo | 3.76% |
| 6-mo | N/A |
| 1-year | -44.95% |
| 3-year | -94.06% |
| 5-year | -99.02% |
| YTD | -9.25% |
| 2023 | -74.47% |
| 2022 | -61.85% |
| 2021 | -43.79% |
| 2020 | 12.50% |
| 2019 | N/A |
Loading social stream, please wait...